Mariner’s Unity Biotechnology UBX Stock Holding History

Mariner’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,007	Closed	-$16K	–	2843
2022 Q3	$16K	Buy	+4,007	New	+$25.3K	﹤0.01%	2398

Other funds holding UBX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner's UBX Position: Q4 2022 in Review

Mariner sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 4,007 shares — an estimated $16K sold.

Mariner first reported a position in UBX in Q3 2022 and held it in 1 quarter. The position peaked at $16K in Q3 2022. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

Mariner reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
Mariner sold 4,007 Unity Biotechnology shares in Q4 2022, an estimated $16K.
Mariner first reported a position in Unity Biotechnology in Q3 2022 and held it in 1 quarter.
Mariner's Unity Biotechnology position peaked at $16K in Q3 2022.
54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Mariner's 13F filing for Q4 2022, filed 14 Feb 2023.